Artelo Biosciences is a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain and neurological conditions.
Clinical Trials: Yes.
PARTNERSHIPS:
2018
The company entered into a global R&D partnership with Syngene International And Aptus Clinical for the clinical development of ART27.13 in oncology. Syngene will be the discovery and development partner providing a pre-clinical data package to support the advancement of ART27.13 for anti-cancer indications. Aptus Clinical will provide clinical development and regulatory expertise to the partnership as well as develop and design an anti-cancer clinical study that is scientifically credible, ethically acceptable and operationally deliverable.
The company entered into an exclusive global option and license agreement with The NEOMED Institute for the advancement of NEO1940. Artelo has a 12-month long option period to evaluate the anti-cancer potential of the compound with the right to exercise an exclusive worldwide license to develop and commercialize NEO1940 as a therapeutic for cancer patients as well as a multi-modal supportive care treatment for cancer patients suffering from anorexia and weight loss.
The company achieved a worldwide licensing agreement with Stony Brook University for a portfolio of fatty acid binding protein inhibitor drug candidates. During the first year of the partnership, the company will collaborate with the Stony Brook University team that was in charge of developing the technology, to identify a lead development compound, develop a pharmaceutically acceptable formulation, and evaluate activity in nonclinical animal models across select indications. In 2020, the company expanded its collaboration with Stony Brook for the the development of lead cancer, pain and inflammation compounds.
2020
The company and the University of Western Ontario with Dr. Steven Laviolette’s laboratory was awarded a research grant by Mitacs where the Mitacs Accelerate grant is expected to fund 50% of research costs evaluating ART26.12 as a potential treatment for anxiety disorders.
The US Patent and Trademark Office issued patent No. 10,604467 for “Solid Forms of Cannabidiol and Uses Thereof,” with claims covering ART12.11, the company’s cocrystal, solid form of CBD and TMP until until the 10th of December, 2038.
The company announced that the National Cancer Institute awarded Stony Brook University a 5-year, 4.2 million USD grant to advance the development of its fatty acid binding protein 5 inhibitor platform. This platform is under exclusive license to Artelo as a potential breakthrough cancer treatment. The grant is intended to support research at Stony Brook University’s Institute of Chemical Biology and Drug Discovery in collaboration with Cold Spring Harbor Laboratory and Artelo Biosciences. Under the grant, the research team will develop and identify the preferred FABP5 inhibitors for potency and selectivity and assess the efficacy of the selected drug candidates in preclinical models, both as single agents and in combination with FDA-approved drugs.
The company expanded on its existing research and worldwide commercial license agreement with The Research Foundation For The State University of New York, Stony Brook. The company plans to select a lead cancer therapeutic compound from its FABP5 inhibitors, as well as to identify additional candidates for pain, inflammation and other conditions, facilitating a potentially significant expansion to the company’s development pipeline.
2021
The company announced a research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of Cancer Cachexia.
2022
The company expanded its collaboration with Trinity College Dublin for the investigation of the molecular basis of fatty acid binding protein inhibition in cancer and the potential of the ART26.12 platform for the treatment of various tumors.
2024
The company with its research on ART26.12 was selected as a finalist in Johnson & Johnson’s innovation challenge which adressed atopic dermatitits using novel approaches.
The company announced that ART26.12 was accepted into the Naional Institute of Health’s Helping to End Addiction Long Term Initiative’s Preclinical Screening Platform for Pain.
2025
The company announced nonclinical results on ART12.11 , its proprietary cocrystal composition of CBD and tetramethylpyrazine which showed results from canine studies showing 2different tablet formulations of ART12.11 achieved CBD and metabolite exposure levels similar or greater to the equivalent dose of Epidiolex.
The company became the first public pharma company to adopt SOL as a reserve asset as it launched a digital asset treasury strategy including an at the market PIPE deal where they issued shares and warrants for a total of $9.475 M AUD. Proceeds were also made to support ongoing pharma R&D operations.